Ashwagandha for Stress and Recovery: What the Human Studies Actually Show

Published June 2026 · 14 min read

If you've spent any time in the supplement aisle — or scrolling through wellness content — you've seen ashwagandha everywhere. It's in gummies, capsules, powders, protein bars, even coffee. The marketing claims range from "crushes cortisol" to "transforms your stress response" to things we won't repeat here because they'd make a pharmacologist wince.

On the other side, you've probably also seen the dismissals. "It's just a root." "Ancient doesn't mean effective." "Show me the data."

Fair enough. Let's actually do that.

We're going to walk through the real human clinical studies on ashwagandha — not animal models, not in-vitro cell studies, not anecdotes from Reddit threads. Double-blind, placebo-controlled, randomized trials in actual people. We'll talk about what they found, what the limitations are, and what it all means practically.

First, some context. Ashwagandha is classified as an adaptogen — a compound that may help your body manage stress more efficiently. That's a loaded term in wellness circles, so let's be specific about the proposed mechanism: ashwagandha appears to modulate the HPA (hypothalamic-pituitary-adrenal) axis, which is the neuroendocrine system that controls your cortisol response. When your brain perceives stress — physical, psychological, environmental — the HPA axis fires up cortisol production. The hypothesis is that ashwagandha helps calibrate this system so it responds proportionally rather than overreacting.

That's the theory. Now let's see what happens when you test it in humans.

What Is Ashwagandha, Actually?

The botanical name is Withania somnifera — that "somnifera" literally means "sleep-inducing," which is a clue about one of its traditional uses. It's a shrub native to India, the Middle East, and parts of Africa, and it's been used in Ayurvedic medicine for over 3,000 years. Traditionally, it was prescribed as a "rasayana" — a rejuvenating tonic meant to promote vitality and longevity.

But traditional use, while interesting, isn't evidence. What matters for our purposes is the chemistry.

The root extract contains a group of naturally occurring compounds called withanolides — steroidal lactones that are the primary bioactive constituents. There are over 40 identified withanolides, with withaferin A and withanolide D being among the most studied. These are the compounds that researchers believe are responsible for ashwagandha's effects on the stress response system.

Here's where it gets important for anyone actually buying ashwagandha: not all ashwagandha products are the same. The raw powdered root contains relatively low and highly variable concentrations of withanolides — anywhere from 0.5% to 2%, depending on growing conditions, harvest timing, and processing. This is why modern clinical research almost exclusively uses standardized extracts.

The two most common standardized forms you'll encounter are:

• KSM-66 — A full-spectrum root extract standardized to contain at least 5% withanolides. It uses a proprietary extraction process based on "green chemistry" principles (no alcohol or chemical solvents). This is the most widely studied form.
• Sensoril — An extract derived from both the root and leaves, standardized to contain at least 10% withanolides. Because it includes leaf material, its withanolide profile differs somewhat from root-only extracts.

This distinction matters because when a study shows that "ashwagandha reduces cortisol," it's showing that a specific standardized extract at a specific dose reduced cortisol. Whether your generic ashwagandha powder from an unknown source would do the same thing is genuinely uncertain. Standardization isn't a marketing gimmick — it's what makes the clinical data applicable to the product you're actually taking.

With that foundation, let's look at the studies.

Study 1: Chandrasekhar et al., 2012 — The Landmark Cortisol Study

This is the study that put ashwagandha on the map for stress research, and it's worth spending some time on because it set the template for everything that followed.

Design: Prospective, double-blind, randomized, placebo-controlled trial. That's the gold standard structure. Neither the participants nor the researchers knew who was getting ashwagandha and who was getting placebo until after data collection was complete.

Participants: 64 adults with a documented history of chronic stress. These weren't people having a bad week — they had sustained, ongoing stress as confirmed by screening assessments. They were randomized into two groups: ashwagandha (n=32) or placebo (n=32).

Intervention: 300mg of KSM-66 ashwagandha root extract, taken twice daily (total 600mg/day), for 60 days.

What they measured: Serum cortisol levels (the objective biomarker), plus three validated psychological assessment tools — the Perceived Stress Scale (PSS), the General Health Questionnaire-28 (GHQ-28), and the Depression Anxiety Stress Scale (DASS).

Results:

• Serum cortisol was reduced by 27.9% in the ashwagandha group versus placebo. That's not a trivial number — a nearly 28% reduction in a stress biomarker is clinically meaningful.
• Perceived Stress Scale scores improved significantly compared to placebo (p<0.0001).
• GHQ-28 scores (measuring overall psychological health) improved substantially.
• Sleep quality, assessed as a secondary outcome, also showed improvement.
• No serious adverse effects were reported.

Why this study matters: It combined objective biomarker data (actual cortisol blood levels) with subjective assessments (how participants felt). When both move in the same direction, that's a stronger signal than either alone. The study design was solid — randomized, blinded, controlled. And the effect size was large enough to be practically relevant, not just statistically significant.

Limitations: 64 participants is a decent but not large sample. The study ran for 60 days, so we don't know about longer-term effects or whether benefits persist after discontinuation. It was conducted at a single site in India. And it specifically used KSM-66 — results may not generalize to other ashwagandha preparations.

Still, as far as adaptogen research goes, this is one of the better-designed studies out there. It gave researchers a clear result and a foundation to build on.

Study 2: Salve et al., 2019 — The Dose-Response Question

One of the most useful things a study can do is answer not just whether something works, but how much you need. That's what this study aimed to do.

Design: Randomized, double-blind, placebo-controlled trial with multiple dosing arms.

Participants: 60 healthy, stressed adults divided into four groups.

Intervention: Three different doses of ashwagandha root extract versus placebo, taken daily for 8 weeks:

• 125mg per day
• 300mg per day
• 600mg per day
• Placebo

What they measured: Hamilton Anxiety Rating Scale (HAM-A), serum cortisol, C-reactive protein (an inflammation marker), blood pressure, heart rate, and sleep quality.

Results:

• Cortisol reduction was dose-dependent — the higher the dose, the greater the reduction. The 600mg group showed the most significant decreases.
• The 600mg group saw the largest improvements in stress scores, sleep quality, and serum cortisol.
• Even the 125mg group showed some improvement over placebo, though the effect was smaller.
• Sleep quality improvements were notable across all dosing groups, with the 300mg and 600mg groups performing best.
• The 600mg group also showed improvements in the inflammatory marker C-reactive protein.

Why this study matters: Dose-response relationships are one of the stronger forms of evidence in pharmacology. If a substance truly has a biological effect, you'd expect to see more effect at higher doses (within a therapeutic range). That's exactly what happened here. This kind of data helps establish that the cortisol reduction isn't a fluke — it follows a logical pattern.

It also gives us practical information: 300-600mg daily appears to be the sweet spot based on this and other research. Lower doses may have some benefit, but the most consistent results show up in that range.

Limitations: 60 participants across four groups means each group only had about 15 people — that's small. Eight weeks is a reasonable timeframe but still not long-term. The exact extract used and its withanolide standardization could influence outcomes.

Study 3: Lopresti et al., 2019 — Beyond Cortisol

This study is particularly interesting because it looked beyond cortisol at a broader hormonal picture, which tells us more about how ashwagandha might be affecting the stress response.

Design: Double-blind, randomized, placebo-controlled trial.

Participants: 60 adults experiencing self-reported high stress but without a diagnosed psychiatric condition. This is a pragmatic population — people who are stressed but not clinically ill.

Intervention: 240mg of ashwagandha extract (standardized to 35% withanolides — a higher concentration than typical KSM-66) daily for 60 days.

What they measured: DASS-21 (Depression, Anxiety, and Stress Scale), morning cortisol, DHEA-S (dehydroepiandrosterone sulfate), and testosterone levels.

Results:

• Significant improvements across all three DASS-21 subscales — depression, anxiety, and stress — compared to placebo.
• Morning cortisol was significantly reduced in the ashwagandha group.
• DHEA-S levels increased compared to placebo. This is the finding that makes this study stand out.
• Testosterone showed a trend toward increase in males, though this was a secondary finding.

Why the DHEA-S finding matters: Here's the context that makes this study particularly valuable. Chronic stress doesn't just elevate cortisol — it tends to suppress anabolic hormones like DHEA-S. DHEA-S is sometimes called the "anti-stress hormone" because it counterbalances many of cortisol's catabolic effects. It supports immune function, mood regulation, and tissue repair.

When you see cortisol going down and DHEA-S going up, that suggests the intervention isn't just suppressing cortisol production (which could have its own problems). Instead, it appears to be rebalancing the stress hormone axis — bringing the ratio of catabolic to anabolic hormones back toward a healthier equilibrium. That's a more nuanced and physiologically meaningful effect than simple cortisol suppression.

Limitations: Same caveats — 60 participants, 60-day duration, single study. The extract used was more concentrated than what's in most commercial products (35% withanolides vs. the typical 5%), so the 240mg dose may deliver a withanolide load similar to a higher dose of less concentrated extracts. This makes direct dose comparisons with other studies tricky.

Study 4: Langade et al., 2019 — The Sleep Connection

Sleep kept showing up as a secondary finding in stress studies, so this team decided to make it the primary focus. Good move.

Design: Double-blind, randomized, placebo-controlled trial designed specifically to assess sleep outcomes.

Participants: 150 participants in total — this is one of the larger ashwagandha studies. Crucially, they included both healthy adults and adults with diagnosed insomnia, which allowed them to see whether effects differed between these populations.

Intervention: 300mg of KSM-66 ashwagandha root extract, taken twice daily (total 600mg/day), for 10 weeks — longer than most ashwagandha studies.

What they measured: Sleep onset latency (how long it takes to fall asleep), sleep efficiency (percentage of time in bed actually spent sleeping), total sleep time, wakefulness after sleep onset, and overall sleep quality using the Pittsburgh Sleep Quality Index (PSQI) — the gold standard sleep assessment tool.

Results:

• Sleep onset latency decreased significantly — participants fell asleep faster.
• Sleep quality (PSQI scores) improved significantly compared to placebo.
• Sleep efficiency improved — more time in bed was spent actually sleeping.
• The effects were more pronounced in the insomnia subgroup — the people who needed it most benefited the most.
• Improvements were observed in both healthy and insomnia participants, but the magnitude was larger in those with poor baseline sleep.
• No next-day grogginess or sedation side effects reported — unlike many pharmaceutical sleep aids.

Why this study matters: This study connects the dots between cortisol and sleep in a meaningful way. We know that elevated evening cortisol is one of the primary physiological drivers of insomnia — your body's stress system is essentially keeping you in a state of alertness when you should be winding down. If ashwagandha is genuinely reducing cortisol, you'd expect to see downstream improvements in sleep quality. And that's exactly what this study found.

The fact that effects were stronger in the insomnia subgroup is also telling. It suggests ashwagandha isn't acting as a sedative (which would affect everyone equally) but rather as a stress-response modulator that particularly benefits people whose sleep is being disrupted by an overactive HPA axis.

Limitations: While 150 participants is larger than most adaptogen studies, it's still modest by pharmaceutical standards. The 10-week duration is better than the typical 8-week study but still doesn't tell us about very long-term use. Subjective sleep measures (questionnaires) were the primary endpoints — polysomnography (objective sleep measurement) would have strengthened the findings considerably.

What the Research Suggests Overall

Let's step back from individual studies and look at the pattern.

Across these four trials — and several others we haven't detailed here — certain findings keep recurring:

Cortisol reduction is the most robust finding. Every well-designed study measuring serum cortisol has found a reduction in the ashwagandha group compared to placebo. The magnitude varies (roughly 20-30% reduction), but the direction is consistent. When multiple independent research groups, using different populations, find the same thing, that raises confidence in the result.

Sleep quality improvements are a consistent secondary finding. Even in studies that weren't designed to measure sleep, it keeps showing up. The Langade study, which was specifically designed around sleep outcomes, confirmed what earlier studies had hinted at. The proposed mechanism makes physiological sense: lower evening cortisol = less hyperarousal = easier sleep onset and better sleep maintenance.

The dose-response relationship adds credibility. The Salve study showed that higher doses (within the studied range) produced bigger effects. This is what you'd expect from a genuinely bioactive compound, and it argues against a purely placebo-driven effect.

The hormonal rebalancing picture is intriguing. Lopresti's finding that DHEA-S increased alongside cortisol reduction suggests ashwagandha isn't simply suppressing cortisol. It may be helping the entire stress-hormone axis recalibrate. This is more aligned with the "adaptogen" concept than simple cortisol suppression would be.

Practical dosing: Based on the available evidence, 300-600mg daily of a standardized extract (typically 5% withanolides or higher) appears to be the most supported dose range. Effects typically become noticeable after 4-8 weeks of consistent daily use. This isn't caffeine — you won't feel it on day one.

What the Research Does NOT Show

We'd be doing you a disservice if we didn't talk about the gaps and limitations. No honest evaluation of ashwagandha research can skip this section.

We don't have long-term data. The longest study in the core literature is 10 weeks. We don't know what happens with 6 months, 1 year, or 5 years of continuous use. Is it safe long-term? Do benefits plateau? Do they diminish? We simply don't have the data to answer those questions confidently. Most practitioners recommend cycling ashwagandha (e.g., 8 weeks on, 2-4 weeks off), but this is based on traditional practice and caution, not clinical evidence.

Sample sizes are modest. The studies we reviewed included between 60 and 150 participants. In pharmaceutical research, Phase III trials typically enroll hundreds or thousands of people. Ashwagandha hasn't had that level of investment in clinical research. Smaller studies are more susceptible to statistical noise and may not capture rare adverse effects.

Most studies use specific branded extracts. KSM-66 dominates the clinical literature. This is partly because the manufacturer funds research (which is standard in the supplement industry but worth noting). If you're using a different ashwagandha product — especially an unstandardized powder — the results from these studies may not apply to what you're actually taking. The withanolide content and profile can vary significantly between products.

Publication bias is possible. Studies with positive results are more likely to be published than studies with null results. This is a systemic problem across all of science, not unique to ashwagandha, but it means the published literature may paint a rosier picture than the full body of conducted research would.

Important contraindications exist:

• Thyroid conditions: Ashwagandha has been shown to increase thyroid hormone levels (T3 and T4) in some studies. If you have hyperthyroidism, Graves' disease, or are on thyroid medication, ashwagandha could potentially interfere. If you have hypothyroidism, the interaction is more nuanced — some practitioners use it supportively, but this absolutely requires medical supervision.
• Pregnancy and breastfeeding: There is insufficient safety data for use during pregnancy or lactation. Most sources recommend avoiding it during these periods.
• Autoimmune conditions: Because ashwagandha may stimulate immune function, it could theoretically worsen autoimmune conditions like lupus, rheumatoid arthritis, or multiple sclerosis. This is precautionary — not well-studied — but worth noting.
• Medication interactions: Ashwagandha may interact with immunosuppressants, sedatives, thyroid medications, and potentially blood sugar-lowering drugs. If you're on any prescription medication, talk to your doctor before adding ashwagandha.

None of this means ashwagandha is dangerous for healthy adults at standard doses. The safety profile in the studies reviewed is actually quite clean — adverse effects were minimal and comparable to placebo. But "generally well-tolerated in 8-week studies of healthy adults" is a different statement than "safe for everyone in all situations indefinitely," and we want to be clear about that distinction.

How We Use Ashwagandha at Pilly Labs

We include ashwagandha in two of our formulations: Adaptogen Vitality Gummies and Reishi Relax Gummies.

In both cases, we use a standardized root extract — not generic powder — because that's what the clinical evidence is built on. The dose is fully disclosed on the label. No proprietary blends, no "ashwagandha matrix," no hiding behind vague terminology. You can see exactly how much you're getting and compare it directly to the doses used in published research.

Our rationale for including ashwagandha specifically is its cortisol-modulating properties. In the Adaptogen Vitality Gummies, it works alongside mushroom adaptogens (like lion's mane and cordyceps) that operate through different biological pathways — neurotrophin support and cellular energy metabolism, respectively. The idea is that addressing stress through multiple mechanisms may be more effective than relying on a single pathway.

In the Reishi Relax Gummies, ashwagandha is paired with reishi mushroom, which has its own body of research around calming and sleep support. The combination targets the stress-sleep connection from complementary angles — HPA axis modulation (ashwagandha) alongside GABAergic and immune-calming pathways (reishi).

We're not claiming these are magic pills. We're saying the ingredients have clinical evidence, the doses are transparent, and the formulation logic is based on published research rather than marketing trends.

The Bottom Line

Ashwagandha has more human clinical evidence behind it than most adaptogens — and certainly more than most supplements that make stress-related claims. The cortisol reduction data is real, replicated, and dose-dependent. The sleep quality improvements are a logical and consistently observed downstream effect. The hormonal rebalancing picture (cortisol down, DHEA-S up) is more nuanced and more interesting than simple "stress relief."

But let's keep perspective.

Ashwagandha is not a miracle cure for stress. No supplement is. Chronic stress is a complex, multifactorial problem that involves your environment, your habits, your psychology, your relationships, and your physiology. A root extract, no matter how well-studied, is not going to override a 70-hour work week, chronic sleep deprivation, or unaddressed emotional issues.

What ashwagandha may offer — based on the evidence we've reviewed — is one useful tool in a larger toolkit. If you're already prioritizing sleep, regular exercise, adequate nutrition, and reasonable stress management, ashwagandha might help your body handle residual stress more efficiently. It appears to help the stress-response system recalibrate rather than remain stuck in overdrive.

That's a modest claim. But it's an honest one, and it's supported by the data.

If you do decide to try ashwagandha, our recommendations based on the research:

• Use a standardized extract (look for KSM-66 or equivalent with stated withanolide content).
• Aim for 300-600mg daily.
• Give it at least 4-8 weeks before evaluating whether it's working for you.
• Take it consistently — this isn't an as-needed supplement.
• Talk to your doctor if you have thyroid issues, autoimmune conditions, or are on medication.

As always, we'll keep updating this article as new research emerges. The evidence base for ashwagandha is growing, and we'll follow wherever it leads — even if that means revising our current conclusions.

References

1. Chandrasekhar, K., Kapoor, J., & Anishetty, S. (2012). A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults. Indian Journal of Psychological Medicine, 34(3), 255-262. doi:10.4103/0253-7176.106022
2. Salve, J., Pate, S., Debnath, K., & Langade, D. (2019). Adaptogenic and anxiolytic effects of ashwagandha root extract in healthy adults: A double-blind, randomized, placebo-controlled clinical study. Cureus, 11(12), e6466. doi:10.7759/cureus.6466
3. Lopresti, A. L., Smith, S. J., Malvi, H., & Kodgule, R. (2019). An investigation into the stress-relieving and pharmacological actions of an ashwagandha (Withania somnifera) extract: A randomized, double-blind, placebo-controlled study. Medicine, 98(37), e17186. doi:10.1097/MD.0000000000017186
4. Langade, D., Kanchi, S., Salve, J., Debnath, K., & Ambegaokar, D. (2019). Efficacy and safety of ashwagandha (Withania somnifera) root extract in insomnia and anxiety: A double-blind, randomized, placebo-controlled study. Cureus, 11(9), e5797. doi:10.7759/cureus.5797
5. Bonilla, D. A., Moreno, Y., Gho, C., Petro, J. L., Odriozola-Martinez, A., & Kreider, R. B. (2021). Effects of Ashwagandha (Withania somnifera) on Physical Performance: Systematic Review and Bayesian Meta-Analysis. Journal of Functional Morphology and Kinesiology, 6(1), 20. doi:10.3390/jfmk6010020
6. Speers, A. B., Cabey, K. A., Soumyanath, A., & Wright, K. M. (2021). Effects of Withania somnifera (Ashwagandha) on Stress and the Stress-Related Neuropsychiatric Disorders Anxiety, Depression, and Insomnia. Current Neuropharmacology, 19(9), 1468-1495. doi:10.2174/1570159X19666210712151556

This article is for informational purposes only and does not constitute medical advice. Always consult with a healthcare provider before starting any new supplement, especially if you have pre-existing medical conditions, are pregnant or breastfeeding, or are taking medications. These statements have not been evaluated by the Food and Drug Administration. Our products are not intended to diagnose, treat, cure, or prevent any disease.

RELATED PRESS RELEASE

AccessNewswire Pilly Labs Mushroom Gummies Reviewed: 2025's Top Adaptogenic Supplement